

St John's DermAcademy Podcasts
by Dr Sarah Drummond

Episode 16: Eczema Therapeutics - Part 1



Professor Catherine Smith
Professor of Dermatology and Therapeutics
St John's Institute of Dermatology
Guy's and St Thomas' NHS Foundation Trust and
King's College London



Dr Andrew Pink
**Consultant Dermatologist and Director of Adult
Clinical Trials Unit**
St John's Institute of Dermatology
Guy's and St. Thomas' NHS Foundation Trust


In this episode we discuss...

- Where conventional systemic agents fit within the evolving landscape of eczema therapeutics
- The biologic agents licensed for use in eczema including their mechanism of action, monitoring requirements and potential side effects.

References and further reading:

- SmPC dupilumab: <https://www.medicines.org.uk/emc/product/11321/smpc#gref>
- SmPC tralokinumab: <https://www.medicines.org.uk/emc/product/12725/smpc#gref>
- NICE guidance – Dupilumab for treating moderate to severe atopic dermatitis:
<https://www.nice.org.uk/guidance/ta534>
- NICE guidance – Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis:
<https://www.nice.org.uk/guidance/ta814>
- BEACON trial information: <https://www.beacontrial.org/>
- Overleaf: Guy's and St Thomas algorithm for Dupilumab-Associated Ocular Surface Disease Prevention and Treatment (**Only valid from 11/01/22 to 11/01/25**)

Dupilumab-Associated Ocular Surface Disease Prevention and Treatment



Development of conjunctivitis in patients treated with dupilumab is unpredictable and predicting the course of any conjunctivitis is also difficult. This treatment pathway can be initiated at any point in dupilumab treatment if a patient develops dupilumab-associated ocular surface disease.

- The initial aim of treatment is to optimise control of any pre-existing allergic eye disease and anticipate a need for topical lubricants to control patients' symptoms.
- Initial prescriptions will be prescribed from the hospital pharmacy to ensure the treatment is started in a timely manner in relation to first dose of dupilumab and supply maintained for the first 3 months of treatment after initiation of any new treatments until next clinical review.
- If topical treatments are continued, further supplies should be obtained from the GP as per the South East London Interface Prescribing policy, or alternatively the prescriber may advise a suitable lubricant product which may be purchased over the counter.
- Tacrolimus 0.1% ointment (Protopic®) should be prescribed from the GP after 3 months initial supply from the hospital if dermatology recommend continuation (amber rated).
- Ciclosporin 1mg/ml eye drops (Ikervis®) should be prescribed from the GP after 3 months initial supply from the hospital if ophthalmology recommend continuation (amber rated).